Journal article
Associations of television viewing time with adults' well-being and vitality
PC Dempsey, BJ Howard, BM Lynch, N Owen, DW Dunstan
Preventive Medicine | Published : 2014
Abstract
Objective: Television (TV) viewing, a common leisure-time sedentary behaviour, is associated adversely with cardio-metabolic health, fatigue, depression and mental health. However, associations of TV viewing time with health-related quality of life attributes are less well understood. We examined associations of TV viewing time with physical well-being, mental well-being and vitality in a large population-based sample of Australian adults. Method: The study sample comprised 4,483 men and 5,424 women (mean age 51. ±. 14. years) from the Australian Diabetes, Obesity and Lifestyle study (1999-2000). Multiple linear regressions examined associations of TV viewing time (h/day) with the SF-36v1 ph..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
This work was supported by the following: National Health and Medical Research Council Program Grant [grant number 566940 to NO], National Health and Medical Research Council/National Heart Foundation Postgraduate Scholarship [grant number 1056320 to BJH], National Health and Medical Research Council Early Career Fellowship [grant number 586727 to BML], Australian Research Council Research Fellowship to DWD [FT100100918] and Senior Principal Research Fellowship [grant number 1003960 to NO]. This study was also supported in part by the Victorian Government's OIS Program. The funders of this study had no role in the data analysis or interpretation of the results. We are most grateful to the following for their support of the study: Commonwealth Department of Health and Aged Care, Abbott Australasia Pty Ltd., Alphapharm Pty Ltd., Aventis Pharmaceutical, AstraZeneca, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust) Pty Ltd., GlaxoSmithKline, Janssen-Cilag (Aust) Pty Ltd., Merck Lipha s.a., Merck Sharp 82 Dohme (Aust), Novartis Pharmaceutical (Aust) Pty Ltd., Novo Nordisk Pharmaceutical Pty Ltd., Pharmacia and Upjohn Pty Ltd., Pfizer Pty Ltd., Roche Diagnostics, Sanofi Synthelabo (Aust) Pty Ltd., Servier Laboratories (Aust) Pty Ltd., BioRad Laboratories Pty Ltd., HITECH Pathology Pty Ltd., the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services, Victorian Department of Human Services and Health Department of Western Australia. Also, we are enormously grateful to the following for their invaluable contribution to the field activities of AusDiab: Annie Allman, Marita Dalton, Adam Meehan, Claire Reid, Alison Stewart, Robyn Tapp and Fay Wilson. The AusDiab Steering Committee consists of Dr. B. Atkins, Dr. S. Bennett, Dr. S. Chadban, Prof. S. Colagiuri, Dr. M. de Courten, Dr. M. D'Embden, Dr. D. Dunstan, Prof. T. Dwyer, Dr. D. Jolley, Dr. P. Magnus, Prof. J. Mathews, Dr. D. McCarty, Prof. K. O'Dea, Dr. P. Phillips, Dr. P. Popplewell, Mr. I. Kemp, Prof. H. Taylor, Prof. T. Welborn and Prof. P. Zimmet. We are most grateful to Parneet Sethi for statistical support; and especially the participants for volunteering their time to be in the study.